Also known as: lung adenocarcinomas
Lung adenocarcinoma is a subtype of lung cancer that develops from cells lining the alveoli and mucus-producing cells. It is currently the most common histologic lung cancer subtype in U.S. incidence data.
New AI model predicts TP53 mutations across 32 cancers. EGFR prediction models vary by ancestry. Breast pathology review finds AI improves accuracy but notes barriers.
New studies present SPARK, an AI framework for tumor analysis, a Cell review of liver cancer hallmarks and treatments, and a call for more research into lung cancer in never-smokers, which was the fifth most common cause of cancer death in 2020.
Research reveals therapy-induced senescent cancer cells and the integrated stress response pathway play dual roles in cancer immunotherapy resistance. The ATF4-LCN2 axis suppresses anti-tumor immunity by promoting immunosuppressive macrophages, while senescent cells can both enhance and inhibit immune responses. These findings highlight new targets for improving immunotherapy efficacy.
New research reveals that different KRAS mutation types create distinct tumor ecosystems with varying immune responses, potentially enabling personalized treatment strategies combining mutation-specific inhibitors with immunotherapy.
For the first time, 70% of cancer patients in the U.S. survive five years or more after diagnosis, according to the American Cancer Society's 2026 report. Advances in immunotherapy, CAR T-cell therapy, and screening technologies have driven significant improvements, particularly for lung cancer and myeloma. The definition of successful cancer care is evolving beyond survival to focus on quality of life and durable remissions.
Researchers develop ultra-sensitive CAR-T cells targeting CD70 for solid tumors and KRASG12V/HLA-A*02:01-specific CAR-T cells for cancers with KRAS mutations, demonstrating efficacy in preclinical models.
A newly published study in Int. J. Mol. Sci. confirms that deuterium concentration directly influences gene expression in lung adenocarcinoma cells, validating HYD LLC's three-decade research on deuterium-depleted water as a complementary cancer therapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07705035 |
DBC-664 in Adult Patients With Solid Tumors |
RECRUITING | PHASE1 |
| NCT07675876 |
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07636252 |
Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma |
RECRUITING | |
| NCT07633626 |
Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib |
RECRUITING | |
| NCT07630246 |
CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS |
NOT_YET_RECRUITING | |
| NCT07481786 |
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases |
RECRUITING | PHASE3 |
| NCT07479095 |
Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma |
RECRUITING | NA |
| NCT07423169 |
Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer |
RECRUITING | NA |
| NCT07416058 |
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07392073 |
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC |
NOT_YET_RECRUITING |
